课题基金 / 基金详情

Mechanisms of amyloid-beta clearance.

Mechanisms of amyloid-beta clearance.
β-淀粉样蛋白清除机制。
批准号:
6837618
负责人:
Brian J Bacskai
金额:
$28.76万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-02-01 至 2007-01-31

项目摘要

项目成果

Brian J Bacskai的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
EXCEED THE SPACE PROVIDED. Transgenic mouse models over-expressing APP develop senile plaques in an age-dependent fashion similar to those found in patients with Alzheimer's disease (AD). Recent evidence shows that active or passive immunotherapy dramatically prevents amyloid-13 deposition in transgenic mice. Clearance of existing amyloid-13 deposits present in Alzheimer's disease patients, in addition to prevention of new plaque formation, will be critical for an effective treatment. Observing senile plaques before and after treatment is the only direct way to measure clearance of existing deposits, but until recently this has not been possible. We have developed novel multiphoton microscopy techniques that allow longitudinal in vivo imaging of individual plaques. Using this approach, we demonstrated clearance of existing plaques in transgenic mice 3-5 days after a single application of antibodies to the cortex. In this application, we propose to test hypotheses about the mechanism of clearance. Aim 1 follows from our observation that clearance can also occur with addition of F(ab')2 fragments, suggesting that Fc-mediated mechanisms are not necessary. We propose a model whereby clearance results from a two-step process involving disaggregation of amyloid-13 deposits via direct biophysical interaction followed by active removal of the amyloid. Aim 2 asks whether systemic immunization, rather than topical application of antibody to cortex, will lead to clearance; if so, we will determine necessary titers and optimal epitopes. Aim 3 takes advantage of in vitro results from several laboratories demonstrating that amyloid-13 binding compounds prevent or reverse formation of amyloid fibrils. We will test whether they are disaggregating agents in vivo. The results will strongly impact the development of treatments aimed at removing senile plaques and the associated neurological damage in Alzheimer's disease. PERFORMANCE SITE ========================================Section End===========================================
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Slow-wave activity as a modifier of the progression of neurodegeneration in Alzheimer's disease
Slow-wave activity as a modifier of the progression of neurodegeneration in Alzheimer's disease
  • 批准号:
    10205286
  • 项目类别:
  • 资助金额:
    $19.5万
  • 财政年份:
    2019
  • 负责人:
    Brian J Bacskai
  • 依托单位:
Astrocytes as governing pathological drivers of neurovascular dysfunction in AD
  • 批准号:
    10584240
  • 项目类别:
  • 资助金额:
    $53.41万
  • 财政年份:
    2017
  • 负责人:
    Brian J Bacskai
  • 依托单位:
CEREBRAL AMYLOID ANGIOPATHY AND MECHANISMS OF BRAIN AMYLOID ACCUMULATION
  • 批准号:
    9884824
  • 项目类别:
  • 资助金额:
    $113.43万
  • 财政年份:
    2016
  • 负责人:
    Brian J Bacskai
  • 依托单位:
国内基金
海外基金
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
  • 批准号:
    22077118
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2020
  • 负责人:
    高楠
  • 依托单位:
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
  • 批准号:
    81870666
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    王海燕
  • 依托单位:
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
  • 批准号:
    81601123
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    17.0万元
  • 批准年份:
    2016
  • 负责人:
    都瑾
  • 依托单位:
APOC1,CLU,SORL1,APOE变异通过调控脂代谢和Abeta水平影响痴呆发病机理的研究
  • 批准号:
    81460203
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    47.0万元
  • 批准年份:
    2014
  • 负责人:
    胡才友
  • 依托单位: